LLY

1,126.9

+3.46%↑

JNJ

228.18

+1.98%↑

ABBV

223.21

+2.13%↑

UNH

395.46

+3.74%↑

MRK

119.52

+3.94%↑

LLY

1,126.9

+3.46%↑

JNJ

228.18

+1.98%↑

ABBV

223.21

+2.13%↑

UNH

395.46

+3.74%↑

MRK

119.52

+3.94%↑

LLY

1,126.9

+3.46%↑

JNJ

228.18

+1.98%↑

ABBV

223.21

+2.13%↑

UNH

395.46

+3.74%↑

MRK

119.52

+3.94%↑

LLY

1,126.9

+3.46%↑

JNJ

228.18

+1.98%↑

ABBV

223.21

+2.13%↑

UNH

395.46

+3.74%↑

MRK

119.52

+3.94%↑

LLY

1,126.9

+3.46%↑

JNJ

228.18

+1.98%↑

ABBV

223.21

+2.13%↑

UNH

395.46

+3.74%↑

MRK

119.52

+3.94%↑

Strona główna・Stock List・AnaptysBio Inc

AnaptysBio Inc

Open

SectorHealthcare

51.21 1.77

Buy Sell

Overview

Share price change

24h

Current

Min

50.14

Max

52.34

Key metrics
By Trading Economics
Income	-102M -53M
Sales	-83M 26M
EPS	-1.843
Profit margin	-206.934
Employees	104
EBITDA	-102M -34M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+57.04% upside

Dividends
By Dow Jones
Next Earnings	4 sie 2026

Market Stats
By TradingEconomics
Market Cap	-430M 1.5B
Previous open	49.44
Previous close	51.21

News Sentiment

By Acuity

20%

80%

42 / 344 Ranking in Healthcare

AnaptysBio Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

3 cze 2026, 23:22 UTC

Earnings

Major Market Movers

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

3 cze 2026, 23:09 UTC

Hot Stocks

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

3 cze 2026, 20:51 UTC

Earnings

Costco Reports 15% Sales Growth in May

3 cze 2026, 20:43 UTC

Earnings

Broadcom 2Q Revenue Climbs on AI Chip Demand

3 cze 2026, 23:48 UTC

Market Talk

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

3 cze 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 cze 2026, 23:35 UTC

Market Talk

Oil Futures Fall on Possible Technical Correction -- Market Talk

3 cze 2026, 23:15 UTC

Market Talk

Earnings

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

3 cze 2026, 22:08 UTC

Hot Stocks

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

3 cze 2026, 21:54 UTC

Market Talk

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

3 cze 2026, 21:18 UTC

Earnings

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

3 cze 2026, 21:15 UTC

Earnings

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

3 cze 2026, 21:13 UTC

Earnings

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

3 cze 2026, 21:13 UTC

Earnings

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

3 cze 2026, 21:12 UTC

Earnings

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

3 cze 2026, 21:09 UTC

Earnings

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

3 cze 2026, 21:03 UTC

Earnings

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

3 cze 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 cze 2026, 20:43 UTC

Earnings

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

3 cze 2026, 20:39 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

3 cze 2026, 20:37 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

3 cze 2026, 20:35 UTC

Earnings

Broadcom Stock Falls Despite Record Results -- Barrons.com

3 cze 2026, 20:21 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

3 cze 2026, 20:17 UTC

Earnings

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

3 cze 2026, 20:17 UTC

Earnings

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

3 cze 2026, 20:15 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

3 cze 2026, 20:15 UTC

Earnings

Broadcom 2Q Adj EPS $2.44 >AVGO

3 cze 2026, 20:15 UTC

Earnings

Broadcom 2Q EPS $1.91 >AVGO

3 cze 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

3 cze 2026, 20:15 UTC

Earnings

Broadcom 2Q Rev $22.19B >AVGO

Peer Comparison

Price change

AnaptysBio Inc Forecast

Price Target

By TipRanks

57.04% upside

12 Months Forecast

Average 80.5 USD 57.04%

High 140 USD

Low 50 USD

Based on 11 Wall Street analysts offering 12 month price targets forAnaptysBio Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Based on 11 analysts giving stock ratings to AnaptysBio Inc - Dist in the past 3 months.

Sentiment

By Acuity

42 / 344 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.